In early TNBC, PD-L1 has consistently been shown to be prognostic but not predictive, with improved pCR rates seen in PD-L1 positive tumours regardless of treatment with ICI or with chemotherapy alone across the KEYNOTE-522, IMpassion031 and GeparNuevo trials. This evidence concerns the gene CD274 and neoplasm.